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polymorphisma b s t r a c t
Cyclophosphamide (Cy) is a prodrug that depends on bioactivation by hepatic cytochrome P450 (CYP) en-
zymes for its cytotoxicity. We evaluated the inﬂuence of single nucleotide polymorphisms (SNPs) of CYP
enzymes on the efﬁcacy of autologous hematopoietic cell transplantation (HCT) for lymphoma. SNPs of 22
genes were analyzed in 93 patients with Hodgkin (n ¼ 52) and non-Hodgkin lymphoma (n ¼ 41) treated with
high-dose Cy followed by autologous HCT between 2004 and 2012. Preparative regimens contained Cy
(120 mg/kg) combined with carmustine/etoposide (n ¼ 61) or Cy (6000 mg/m2) with total body irradiation
(n ¼ 32). Lack of complete remission as measured by pretransplant positron emission tomography was the
sole clinical factor associated with increased risk of relapse (HR, 2.1). In genomic analysis, we identiﬁed a
single SNP (rs3211371) in exon 9 (C > T) of the CYP2B6 gene (allele designation 2B6*5) that signiﬁcantly
impacted patient outcomes. After adjusting for disease status and conditioning regimen, patients with the
CYP2B6*1/*5 genotype had a higher 2-year relapse rate (HR, 3.3; 95% CI, 1.6 to 6.5; P ¼ .041) and decreased
overall survival (HR, 13.5; 95% CI, 3.5 to 51.9; P ¼ .008) than patients with the wild-type allele. Two-year
progression-free survival for patients with 2 hypofunctional CYP2B6 variant genotypes (*5 and *6) was
only 11% (95% CI, 1% to 39%) compared with 67% (95% CI, 55% to 77%) for patients with the wild-type CYP2B6*1
allele in exon 9. Our results suggest that CYP2B6 SNPs inﬂuence the efﬁcacy of high-dose Cy and signiﬁcantly
reduce the success of autologous HCT for lymphoma patients with the CYP2B6*5 variant.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemo-/radiotherapy with autologous he-
matopoietic cell transplantation (HCT) often cures patients
with recurrent chemotherapy-sensitive lymphoma. Although
most patients attain remission after autologous HCT, disease
progression is the most common cause of treatment failure,
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tive regimens for lymphoma commonly contain the potent
alkylator cyclophosphamide (Cy) in combination with car-
mustine, etoposide, and cytarabine; carmustine and etoposide
(CyBV); or in combination with total body irradiation (Cy/TBI)
[1,3-5]. Cy is a prodrug that needs to be biotransformed to its
metabolite 4-hydroxycyclophosphamide (4-hydroxyCy) by
hepatic cytochrome P450 (CYP) enzymes. 4-HydroxyCy dif-
fuses from hepatocytes to plasma and spontaneously de-
grades to aldophosphamide and then to phophorodiamidic
mustard and acrolein, both of which contribute to cytotoxicity
by interfering with DNA replication [6-8]. Patients treated
with high-dose Cy show a large interpatient variability in
levels of Cy (3-fold) and 4-hydroxyCy (8-fold), which could be
partly due to variable expression and function of CYP en-
zymes. In some studies, germline single nucleotide poly-
morphisms (SNPs) in the CYP2B6 enzyme signiﬁcantly
reduced Cy bioactivation [8,9]. However, it is unknown
whether SNPs in genes with known relevance to Cy phar-
macokinetics or pharmacodynamics inﬂuence the efﬁcacy of
autologous HCT for lymphoma.
METHODS
Study Design
Using prospectively collected data in the University of Minnesota Blood
and Marrow Transplantation Database (clinical trial numbers NCT00345865
and NCT00005985 registered at clinicaltrials.gov), we studied 93 patients
with non-Hodgkin (NHL) and Hodgkin lymphoma (HL) who underwent
high-dose Cy containing chemotherapy followed by autologous HCT be-
tween 2004 and 2012. The University of Minnesota Institutional Review
Board approved transplant protocols and study design, and all patients gave
written informed consent and were treated in accordance with the Helsinki
Declaration.
The myeloablative preparative regimen included CyBV (Cy 1500 mg/m2/
d i.v. 4 days, carmustine 300mg/m2 i.v. day 1, and VP16 150mg/m2 twice a
day i.v.  4 days) or Cy/TBI (Cy 60 mg/kg i.v.  2 days plus TBI 165 cGy twice
daily  4 days) and supportive care as previously reported [2]. All patients
received allopurinol, and no other CYP450 inhibitors or inducers were
allowed during Cy infusion. Disease status was assessed pretransplant and
3 months post-transplant by positron emission tomography (PET) according
to criteria described by Cheson [10] and by post-transplant computed to-
mography at day 28 and at 6, 12, and 24 months.
Genotyping
After informed consent was obtained, peripheral blood leukocytes from
patientswere collected and stored in liquid nitrogen. DNAwas obtained from
peripheral blood mononuclear cells using a DNA/RNA isolation kit (Qiagen,
Valencia, CA). SNPs and genes of importance to Cy pharmacokinetics and
pharmacodynamics were selected by using information from the PharmGKB
database (https://www.pharmgkb.org) and literature screening. iPLEX
(Sequenom, San Diego, CA), which uses matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry (MALDI-TOF)ebased chemistry,
was used to genotype 39 SNPs spanning 22 genes (Supplemental Table 1).
CYP2B6 rs3211371 SNP was genotyped using Taqman SNP genotyping assay
(Applied Biosystems by Life Technologies, Grand Island, NY) (ID no.
C_30634242_40; samples with known genotype were used as controls). Of
the total 41 SNPs genotyped,16 occurredwith theminimum allele frequency
of less than 10% and were not included in the analysis.
Statistical Methods
The primary endpoint was the cumulative incidence of relapse at
2 years. Kaplan-Meier estimates of survival and cumulative incidence esti-
mates of nonrelapse mortality and relapse were calculated; multivariable
Cox regression determined factors associated with outcomes [11-13]. Each
SNP was modeled as a categorical variable by using the homozygote of the
most common allele as the reference category and was adjusted for disease
status (complete remission [CR] versus no CR) and conditioning regimen. If
the frequency of the homozygous variant allele was <5%, this group was
combined with the heterozygous group. Twenty-ﬁve SNPs with a minimum
allele frequency 10%were included in the analysis (Supplemental Table 1).
Probability values were corrected for multiple testing using the Holm
method to control the family-wise error rate at 5% [14]. Analyses were
performed using SAS (version 9.3, SAS Institute, Cary, NC) and the R geneticspackage (version 3.0). Median post-HCT follow-up among survivors was
4 years (range, 1 to 8 years).
RESULTS
Gene Polymorphism Frequencies
Ninety-three patients with lymphoma (52 HL, 41 NHL)
were evaluated for association of transplant outcomes with
SNPs in 22 genes of importance to Cy pharmacokinetics and
pharmacodynamics. Gene names, minimum allele frequency,
and raw P values for hazard ratios for relapse are summa-
rized in Supplemental Table 1. The genotypes were similar to
those reported in the literature for populations of European
origin in accordance with Hardy-Weinberg equilibrium.
Patient and Transplant Characteristics
The median age of the entire cohort was 45 years (range,
26 to 65). Both genders were equally represented, and 90%
were white (Table 1). Patients with NHL received Cy/TBI
regimen (n ¼ 31) or CyBV (n ¼ 9); all 52 HL patients received
CyBV (Table 1). Median time from diagnosis to HCT was
15 months (range, 4 to 236). Most patients (94%) were che-
mosensitive, and 59% were PET negative before transplant
(Table 1). Only 4 patients were chemoresistant; all 4 patients
had HL.
Transplant Outcomes
We ﬁrst studied the impact of clinical variables (age,
gender, performance status, lymphoma subtype, disease
status pretransplant, conditioning type, graft source, and
time from diagnosis to transplant) on relapse and
progression-free survival (PFS) in univariate analyses
(Table 2). As expected, pretransplant disease status other
than CR signiﬁcantly increased the risk of relapse (hazard
ratio, 2.1; P ¼ .02). Other factors such as age, gender, lym-
phoma histology, conditioning regimen, pretransplant per-
formance status, and interval from diagnosis to transplant
did not inﬂuence relapse or PFS (Table 2).
Relapse and Survival by CYP Polymorphism
We identiﬁed a single SNP (rs3211371) in exon 9 (C>T) of
the CYP2B6 gene (allele designation 2B6*5) that signiﬁcantly
affected transplant outcomes. Twenty-one patients (23%)
were heterozygous (CYP2B6*1/*5; CT genotype) and 71 (76%)
were wild-type for rs3211371 (CYP2B6*1/*1; CC genotype).
One individual was excluded because of failed genotyping.
Patient age, gender, and race (>90% white) were similar
between the 2 genotype groups (CYP2B6*1/*1 versus
CYP2B6*1/*5; Table 1). Most patients in both groups were in
CR (61% and 62%) pretransplant by PET imaging. Patients
with the CYP2B6*5 variant more often had NHL, Cy/TBI
conditioning, and chemosensitive lymphoma; the wild-type
cohort had more HL patients, including 4 with
chemotherapy-refractory disease (Table 1). After adjusting
for disease status (CR versus no CR) and conditioning
regimen, the 2-year cumulative incidence of relapse was
signiﬁcantly higher with the CYP2B6*1/*5 variant (67%; 95%
conﬁdence interval [CI], 45% to 87%) compared with wild-
type CYP2B6*1/*1 (33%; 95% CI, 23% to 44%; P ¼ .041). As a
result, adjusted PFS was inferior among patients with the
CYP2B6*1/*5 variant compared with those with the wild-
type CYP2B6*1/*1 variant (HR 3.3; 95% CI, 1.6 to 6.5;
P ¼ .001; adjusted P ¼ .041). Similarly, 2-year overall survival
decreased to 52% (95% CI, 30% to 71%) among patients with
the CYP2B6*1/*5 variant as compared with 96% (95% CI, 87%
to 99%; P ¼ .008) for those with the wild-type variant
Table 1
Patient and Transplant Characteristics by CYP2B6 Polymorphism
All Patients CYP2B6*1/*1 CYP2B6*1/*5 P
Total 92 (100) 71 (100) 21 (100)
Median age,
yr (range)
45 (5-71) 45 (5-71) 46 (10-69) .20
Male gender 51 (55) 38 (54) 13 (62) .62
Race
White 83 (90) 64 (90) 19 (90) .29





80%-90% 47 (51) 38 (54) 9 (43)
100% 41 (45) 31 (44) 10 (48)
Lymphoma type
HL 52 (57) 43 (61) 9 (43) .21
NHL 40 (43) 28 (39) 12 (57)
Follicular 4 (4) 4 (6) 0 (0)
Diffuse large
B cell
20 (22) 12 (17) 8 (38)
Mantle cell 12 (13) 9 (13) 3 (14)
T cell 3 (3) 2 (3) 1 (5)
Not otherwise
classiﬁed
1 (1) 1 (1) 0 (0)
Disease status
CR1*/PR1 19/1 (22) 12/1 (18) 7/0 (33) .91
CR2 35 (38) 30 (42) 5 (24)
Induction failure
sensitive
11 (12) 8 (11) 3 (14)
PR 2 sensitive 22 (24) 16 (23) 6 (29)
Chemotherapy
resistanty
4 (4) 4 (6) 0 (0) .57
Conditioning
CyBV 61 (66) 51 (72) 10 (48) .06





14 (15) 9 (13) 5 (24) .30




15 (4-236) 17 (5-138) 14 (4-236) .42
Median follow-up,
yr (range)
3.9 (1.0-8.4) 3.5 (1.0-8.4) 5.2 (2.0-8.4) .05
Values are number of cases with percents in parentheses, except where
otherwise noted. Demographic factors were compared between 2B6*5 and
wild-type 2B6*1*1 genotypes using Fisher’s exact test for categorical factors
and 2-sided Wilcoxon test for continuous factors. PR indicates partial
remission.
* CR1 patients had mantle cell lymphoma (n ¼ 10), transformed lym-
phoma (n ¼ 4), and HL (n ¼ 4).
y All patients with chemoresistant disease had HL.
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nosis was observed for patients with the CYP2B6*1/*5 variant
compared with the wild-type variant (PFS: NHL, 33% versus
68%; HL, 22% versus 73%).
Notably, all 8 non-CR patients with the CYP2B6*1/*5
genotype relapsed at a median of 5 months post-transplant
compared with 12 of 28 non-CR patients with the wild-
type genotype. Furthermore, patients with both the
CYP2B6*6 allele (carriers of rs3745274 and rs2279343 on
exons 4 and 5) and CYP2B6*1/*5 genotype (n ¼ 9) had a 2-
year PFS of only 11% (95% CI, 1% to 39%) compared with
67% (95% CI, 55% to 77%) for 71 patients who expressed the
wild-type CYP2B6*1/*1 allele in exon 9.
We catalogued all Cy-associated toxicities and observed
no grade 4 adverse events or deaths due to cardiotoxicity,
veno-occlusive liver disease, or hemorrhagic cystitis. There
was no nonrelapse mortality within 2 years.
DISCUSSION
We report a novel association between a germline
CYP2B6*5 polymorphism and reduced efﬁcacy of high-dose
Cy-containing chemotherapy in lymphoma. CYP2B6 is the
predominant enzyme that activates Cy at higher concentra-
tions [8,15]. In autologous HCT, the preparative regimen,
which consist of high-dose chemotherapy and/or TBI, is
administered with the goal of eliminating malignant cells.
The Cy dose used in myeloablative preparative regimens is at
its extreme and is tolerable only if combinedwith autologous
stem cell rescue to support hematopoiesis. Helsby et al. [15]
showed reduced conversion of Cy in human liver micro-
somes with the CYP2B6*5C>T SNP variant in vitro. By testing
recombinant CYP2B6 enzymes, it was found that the *5
variant expressed lower levels of CYP2B6 protein and
resulted in 50% less 4-hydroxyCy compared with the wild-
type variant [8,15]. Our results suggest that individuals
with the germline CYP2B6*5 variant respond poorly to very
high-dose Cy-containing therapy. High relapse and inferior
survival after a Cy-containing preparative regimen can be
explained, at least in part, by decreased biotransformation to
4-hydroxy-Cy, aldophosphamide, and its products pho-
phorodiamidic mustard and acrolein; this results in the
subsequent loss of Cy’s antilymphoma activity.
Although several groups have examined the clinical impact
of CYP allelic variation in allogeneic donor HCT [6,16-18], there
is a lack of studies examining autologous HCT where the
response is entirely dependent on potent chemotherapy. In
allogeneic sibling transplant recipients with leukemia, Rocha
et al. [16] studied pharmacogene polymorphisms and found
the CYP2B6 family, particularly *2A and *6, were associated
with mucositis, hemorrhagic cystitis, and veno-occlusive liver
disease; however, the event frequency was quite low. In
addition, the relapse rate in this study was too low (10%) to
detect a differential impact of pharmacogene polymorphism
on leukemia control. In another study, Black et al. [17] found
that CYP2B6*5 was associated with less toxicity < 100 days
after transplantation andmodestly increased relapse risk after
myeloablative Cy/TBI allogeneic donor HCT for acute leuke-
mia. It is notable that despite substantial differences in this
and our study, these results are consistent with ours and
support poor in vivo bioactivation of Cy in patients with the
CYP2B6*5 SNP. Melanson et al. [18] examined allogeneic HCT
recipients with mixed diagnosis and showed no difference in
nonrelapse mortality and worse PFS among recipients with
the CYP2B6*1/*4 and *4/*5 genotypes; however, the CYP2B6*5
and *1/*1 (wild-type) gentoypes were combined into a singlecategory, and therefore the inﬂuence of individual alleles was
not reported. The complex nature of the CYP2B6 haplotypes
generated by combination of the SNPs, allele designation
based on co-occurrence of multiple SNPs, and inconsistencies
among reported studies on the CYP allele nomenclature all
limit the value of study comparisons [19-21].
Several conditioning regimens have been evaluated for
lymphoma. Some do not contain Cy (eg, carmustine, etoposide,
cytarabine, melphalan [BEAM]). Two studies reported that the
BEAM regimen yielded better PFS (58%) compared with Cy/TBI
(31%) or CyBV (40%); however, comparisons are retrospective
and include historical cohorts [5,22]. Differences in efﬁcacy
could be related to the fact that the CYP2B6*5 polymorphism
occurs in 9% to 14% of whites and 2% to 9% of African Ameri-
cans. The German CLL group recently reported lower response
rates among patients with the CYP2B6*6 genotype compared
with wild-type after Cy, ﬂudarabine, and rituximab for chronic
Table 2




Age (per 10-year increase) 1.0 (.8-1.2) .78
Gender
Male 1.0
Female .7 (.3-1.3) .25
Karnofsky performance score




Diffuse large B cell 1.1 (.5-2.4) .78
Mantle cell .6 (.2-1.9) .35
Disease status before HCT
In CR by PET 1.0
Not in CR 2.1 (1.1-4.1) .02
Conditioning
CyBV 1.0
Cy/TBI .7 (.3-1.3) .25
Graft source
Marrow  PBSCs 1.0 (.4-2.5) .95
PBSCs 1.0
Months from diagnosis to




*1/*5 2.8 (1.4-5.4) < .01
PBSCs indicates peripheral blood stem cells.
Figure 1. Two-year cumulative incidence of relapse (A) and overall survival
(B) in adults with lymphoma by CYP2B6 genotype. Hazard ratios are adjusted
for disease status and conditioning. Probability values are adjusted for mul-
tiple tests using Holm’s method. *1/*1 represents the wild-type allele.
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about 10% to 40% of whites with CYP2B6*6 being the most
frequent followed by CYP2B6*5 [9]. In our series, about 10% of
patients had both CYP2B6*5 and CYP2B6*6 allelic variants, and
relapse among these patients was particularly high, suggesting
a detrimental effect on CYP2B6 function.
Limitations of our study include smaller sample size and a
limited number of patients in each histology group; there-
fore, validation in larger study in patients receiving high-
dose Cy is warranted. The ease and portability of the
Taqman SNP genotyping assay for 2B6*5 allow imple-
mentation to the clinic. Although a prospective study
correlating the CYP2B6*5 SNP with Cy metabolite levels is
underway at our center, our observations suggest that indi-
vidualized Cy dosing based on CYP genotype could be
applied in the future. Alternatively, conditioning, such as
BEAM, may be preferable in transplant candidates having an
adverse CYP2B6*5 polymorphism. Given themany anticancer
and immunosuppressive applications of Cy, for example
post-transplant Cy use in haploidentical HCT, our results may
have broader clinical implications [21].ACKNOWLEDGMENTS
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Graft-versus-host diseasea b s t r a c t
Graft-versus-host disease, iron overload, and infections are the major causes of liver dysfunction in allogeneic
hematopoietic stem cell transplantation (AHSCT) recipients. We investigated the relationship between serum
iron parameters and the levels of transforming growth factor-b (TGF-b), ﬁbroblast growth factor (FGF),
endothelin-1 (ET-1), and nitric oxide (NO) as predictors of chronic liver injury in 54 AHSCT recipients who
survived at least a year after transplantation. Serum samples from patients were obtained for the evaluation
of ET-1, TGF-b, FGF, NO, and nontransferrin bound iron at the ﬁrst year follow-up visit using commercially
available ELISA kits. Patients were categorized depending on serum ferritin and transferrin saturation levels.
The parameters were compared between the groups, and survival analysis was also performed. Most of the
AHSCT recipients (81.5%) were in complete remission during the study. After a median follow-up time of 73
months (range, 13 to 109 months), 72.2% of the patients were alive. Mean serum levels of ET-1, NO, TGF-b, and
FGF were 81.54  21.62 mmol/mL, 31.82  26.42 mmol/mL, 2.56  0.77 ng/mL, and 50.31  32.69 pg/mL,
respectively. Nineteen patients (35.2% of the cohort) had serum ferritin levels higher than 1000 ng/mL. Mean
